SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-23-204428
Filing Date
2023-08-07
Accepted
2023-08-07 07:01:50
Documents
58
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q d470906d10q.htm   iXBRL 10-Q 1255606
2 EX-31.1 d470906dex311.htm EX-31.1 6607
3 EX-31.2 d470906dex312.htm EX-31.2 6598
4 EX-32.1 d470906dex321.htm EX-32.1 3242
5 EX-32.2 d470906dex322.htm EX-32.2 3161
  Complete submission text file 0001193125-23-204428.txt   5242453

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA vinc-20230630.xsd EX-101.SCH 30254
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE vinc-20230630_cal.xml EX-101.CAL 28537
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vinc-20230630_def.xml EX-101.DEF 182538
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE vinc-20230630_lab.xml EX-101.LAB 312025
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vinc-20230630_pre.xml EX-101.PRE 262695
52 EXTRACTED XBRL INSTANCE DOCUMENT d470906d10q_htm.xml XML 815700
Mailing Address 260 SHERIDAN AVENUE SUITE 400 PALO ALTO CA 94306
Business Address 260 SHERIDAN AVENUE SUITE 400 PALO ALTO CA 94306 650-800-6676
Vincerx Pharma, Inc. (Filer) CIK: 0001796129 (see all company filings)

IRS No.: 833197402 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39244 | Film No.: 231145556
SIC: 2834 Pharmaceutical Preparations